Contribute Try STAT+ Today

We’re in a new phase of the Covid-19 pandemic in which new mutations will have to be consistently monitored — especially as the vaccine race continues. This reality is something I’m always thinking about in my role in financial services supporting health care clients at J.P. Morgan.

How will these mutations affect the business of health care — and how can clients and organizations best prepare — for next month and for the years to come? And how are health care business leaders supposed to model and implement strategies when there exists such a wide range of potential outcomes stemming from new virus variants?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment